Evidence map›Paper›PMID 34220819›Full record

Trial reportFrontiers in immunology2021

Immunogenicity and Efficacy of Pneumococcal Conjugate Vaccine (Prevenar13

Geofrey Makenga, George Mtove, J Kevin Yin, Abubakary Mziray, Veneranda M Bwana, William Kisinza, Julius Mjema, Ben Amos, Laura Antony, Delane Shingadia and 2 more

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact, top 90% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
  2. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 3 countries.

Geofrey MakengaNational Institute for Medical Research (NIMR), Amani Research Center, Muheza, Tanzania.
George MtoveNational Institute for Medical Research (NIMR), Amani Research Center, Muheza, Tanzania.
J Kevin YinFaculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.
Abubakary MzirayNational Institute for Medical Research (NIMR), Amani Research Center, Muheza, Tanzania.
Veneranda M BwanaNational Institute for Medical Research (NIMR), Amani Research Center, Muheza, Tanzania.
William KisinzaNational Institute for Medical Research (NIMR), Amani Research Center, Muheza, Tanzania.
Julius MjemaSt Augustine's, Hospitali Teule, Private Bag, Tanga, Tanzania.
Ben AmosSt Augustine's, Hospitali Teule, Private Bag, Tanga, Tanzania.
Laura AntonyFaculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.
Delane ShingadiaGreat Ormond Street Hospital for Children NHS Trust, London, United Kingdom.
Shahin OftadehNSW and ACT Pneumococcal Reference Laboratory, Centre for Infectious Diseases and Microbiology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead, NSW, Australia.
Robert BooyFaculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.
National Institute for Medical Research · TZRajabu St Augustine's, Hospitali Teule · TZThe University of Sydney · AUGreat Ormond Street Hospital · GBNational Centre for Immunisation Research & Surveillance · AUWestmead Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In every year, up to one million children die due to pneumococcal disease. Children infected with Human Immunodeficiency Virus (HIV) are mostly affected, as they appear to have higher rates of pneumococcal carriage and invasive disease. Successful immunity is dependent on mounting a sufficient immune response to the vaccine. We conducted a double blinded crossover randomised controlled trial to determine the serum antibody response (≥4-fold and geometric mean concentration) to pneumococcal vaccine (PCV13) serotypes at 3 months after second vaccination. We also determined the number and proportion of children carrying new (not present at baseline) vaccine serotypes of Clinical Trial Registration: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=335579, identifier ACTRN12610000999033.

Indexed as

HIV InfectionsAcquired Immunodeficiency SyndromeAdolescentAntibodies, BacterialCarrier StateChildChild, PreschoolCross-Over StudiesDouble-Blind MethodFemaleHumansInfantMalePneumococcal InfectionsPneumococcal VaccinesSerogroup13-valent pneumococcal vaccineAntibodies, BacterialPneumococcal VaccinesVaccines, Conjugatecarriage acquisitionefficacyimmunocompromised childrenimmunogenicityPrevenar 13prevention

Identifiers

PMID34220819
PMCPMC8248180
OpenAlexW3175500967

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.